SG11201804597TA - Vaccination with mica/b alpha 3 domain for the treatment of cancer - Google Patents
Vaccination with mica/b alpha 3 domain for the treatment of cancerInfo
- Publication number
- SG11201804597TA SG11201804597TA SG11201804597TA SG11201804597TA SG11201804597TA SG 11201804597T A SG11201804597T A SG 11201804597TA SG 11201804597T A SG11201804597T A SG 11201804597TA SG 11201804597T A SG11201804597T A SG 11201804597TA SG 11201804597T A SG11201804597T A SG 11201804597TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- cancer
- rule
- alpha
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 239000010445 mica Substances 0.000 title abstract 2
- 229910052618 mica group Inorganic materials 0.000 title abstract 2
- 238000002255 vaccination Methods 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/001139—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/34—Antigenic peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -' Organization International Bureau nvolsi .... ......„,„1 (43) International Publication Date r 8 June 2017 (08.06.2017) W I P0 1 PCT ID Hit (10) WO International 2017/096374 1111111111111111111111111111111111111111111111111111111111111t111111111111111 Publication Number Al (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, A61K 39/00 (2006.01) A61K 47/00 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, PCT/US2016/064969 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (22) International Filing Date: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 5 December 2016 (05.12.2016) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (25) Filing Language: English ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 62/263,377 4 December 2015 (04.12.2015) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/422,454 15 November 2016 (15.11.2016) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: DANA-FARBER CANCER INSTITUTE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, INC. [US/US]; 450 Brookline Avenue, Boston, Massachu- LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, setts 02215 (US). SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (72) Inventors: WUCHERPFENNIG, Kai; 67 Highland Road, GW, KM, ML, MR, NE, SN, TD, TG). Brookline, Massachusetts 02445 (US). BADRINATH, Declarations under Rule 4.17: Soumya; 111 Queensbury Street, Apt. C, Boston, Mas- - as to applicant's entitlement to apply for and be granted a sachusetts 02215 (US). patent (Rule 4.170) (74) Agents: ELRIFI, Ivor et al.; Cooley LLP, 1299 Published: Pennsylvania Avenue Suite 700, Washington, District of Columbia 20004 (US). — with international search report (Art 21(3)) (81) Designated States (unless otherwise indicated, for every — with sequence listing part of description (Rule 5.2(a)) kind AE, AG, AL, AM, of national protection available): AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (54) Title: VACCINATION WITH MICA/B ALPHA 3 DOMAIN FOR THE TREATMENT OF CANCER Figure 11A 250 u) co z N i 200 fE ri) 150 (15 § 100 z Ca. 6- 50 1-1 d .4t = 0 a A alWill A IN C..$4\ en C) 'A CI P C IN Il (57) : The present invention provides compositions and methods for treating cancer in a subject by eliciting an immune re - 0 sponse against a MIC alpha 3-domain polypeptide. ei 0
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562263377P | 2015-12-04 | 2015-12-04 | |
| US201662422454P | 2016-11-15 | 2016-11-15 | |
| PCT/US2016/064969 WO2017096374A1 (en) | 2015-12-04 | 2016-12-05 | Vaccination with mica/b alpha 3 domain for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201804597TA true SG11201804597TA (en) | 2018-06-28 |
Family
ID=57590885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201804597TA SG11201804597TA (en) | 2015-12-04 | 2016-12-05 | Vaccination with mica/b alpha 3 domain for the treatment of cancer |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US10993971B2 (en) |
| EP (1) | EP3383426A1 (en) |
| JP (3) | JP7099956B2 (en) |
| KR (1) | KR20180088458A (en) |
| CN (1) | CN108770343A (en) |
| AU (3) | AU2016362597C1 (en) |
| BR (1) | BR112018010705A8 (en) |
| CA (1) | CA3005910A1 (en) |
| CL (3) | CL2018001470A1 (en) |
| CO (1) | CO2018006642A2 (en) |
| CR (2) | CR20230116A (en) |
| CU (2) | CU20210061A7 (en) |
| EA (1) | EA201891287A1 (en) |
| IL (1) | IL259490A (en) |
| MX (2) | MX2018006785A (en) |
| MY (1) | MY199248A (en) |
| NZ (1) | NZ742663A (en) |
| PE (2) | PE20181158A1 (en) |
| PH (1) | PH12018501170A1 (en) |
| RU (2) | RU2747296C2 (en) |
| SG (1) | SG11201804597TA (en) |
| TN (1) | TN2018000187A1 (en) |
| WO (1) | WO2017096374A1 (en) |
| ZA (1) | ZA202204223B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3773708A2 (en) | 2018-04-03 | 2021-02-17 | Sanofi | Antigenic epstein barr virus polypeptides |
| JP2021519596A (en) * | 2018-04-03 | 2021-08-12 | サノフイＳａｎｏｆｉ | Ferritin protein |
| MX2020010199A (en) | 2018-04-03 | 2021-01-08 | Sanofi Sa | Antigenic respiratory syncytial virus polypeptides. |
| EP3773697A1 (en) | 2018-04-03 | 2021-02-17 | Sanofi | Antigenic ospa polypeptides |
| JP2023532852A (en) | 2020-07-07 | 2023-08-01 | キャンキュア， エルエルシー | MIC Antibodies and Binding Agents and Methods of Their Use |
| CN116396398B (en) * | 2023-01-16 | 2024-07-16 | 四川大学 | A method for achieving controllable self-assembly of ferritin nanoparticles and a nanoparticle antigen display platform based on the method |
| WO2024222886A1 (en) * | 2023-04-28 | 2024-10-31 | 北京先声祥瑞生物制品股份有限公司 | Mrna tumor vaccines for mica/b target |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4709017A (en) | 1985-06-07 | 1987-11-24 | President And Fellows Of Harvard College | Modified toxic vaccines |
| US4950740A (en) | 1987-03-17 | 1990-08-21 | Cetus Corporation | Recombinant diphtheria vaccines |
| DE3841091A1 (en) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | SYNTHETIC ANTIGENS, METHOD FOR THEIR PRODUCTION AND THEIR USE |
| ES2055785T3 (en) | 1989-01-17 | 1994-09-01 | Eniricerche Spa | SYNTHETIC PEPTIDES AND THEIR USE AS UNIVERSAL VEHICLES FOR THE PREPARATION OF IMMUNOGENOUS CONJUGATES SUITABLE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES. |
| JPH04506662A (en) | 1989-07-14 | 1992-11-19 | アメリカン・サイアナミド・カンパニー | Cytokinin and hormone carriers for conjugate vaccines |
| US5073627A (en) | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
| IT1237764B (en) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | SYNTHETIC PEPTIDES USEFUL AS UNIVERSAL CARRIERS FOR THE PREPARATION OF IMMUNOGENIC CONJUGATES AND THEIR USE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES. |
| SE466259B (en) | 1990-05-31 | 1992-01-20 | Arne Forsgren | PROTEIN D - AN IGD BINDING PROTEIN FROM HAEMOPHILUS INFLUENZAE, AND THE USE OF THIS FOR ANALYSIS, VACCINES AND PURPOSE |
| ATE128628T1 (en) | 1990-08-13 | 1995-10-15 | American Cyanamid Co | FIBER HEMAGGLUTININ FROM BORDETELLA PERTUSSIS AS A CARRIER FOR CONJUGATE VACCINE. |
| IT1262896B (en) | 1992-03-06 | 1996-07-22 | CONJUGATE COMPOUNDS FORMED FROM HEAT SHOCK PROTEIN (HSP) AND OLIGO-POLY-SACCHARIDES, THEIR USE FOR THE PRODUCTION OF VACCINES. | |
| CA2135052A1 (en) | 1992-05-06 | 1993-11-11 | R. John Collier | Diphtheria toxin receptor-binding region |
| IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
| US5917017A (en) | 1994-06-08 | 1999-06-29 | President And Fellows Of Harvard College | Diphtheria toxin vaccines bearing a mutated R domain |
| US6455673B1 (en) | 1994-06-08 | 2002-09-24 | President And Fellows Of Harvard College | Multi-mutant diphtheria toxin vaccines |
| CA2271720A1 (en) | 1996-10-31 | 1998-05-07 | Human Genome Sciences, Inc. | Streptococcus pneumoniae polynucleotides and sequences |
| GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
| WO2000056358A2 (en) | 1999-03-19 | 2000-09-28 | Smithkline Beecham Biologicals S.A. | Vaccine against streptococcus pneumoniae capsular polysaccharides |
| WO2000061761A2 (en) | 1999-04-09 | 2000-10-19 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
| GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
| US20030035806A1 (en) | 2001-05-11 | 2003-02-20 | D'ambra Anello J. | Novel meningitis conjugate vaccine |
| CA2462455C (en) | 2001-10-01 | 2012-07-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Development of a preventive vaccine for filovirus infection in primates |
| US6706305B2 (en) | 2001-10-31 | 2004-03-16 | Conagra Foods Inc. | Low glycemic index bread |
| US7097841B2 (en) * | 2002-05-10 | 2006-08-29 | New Century Pharmaceuticals, Inc. | Ferritin fusion proteins for use in vaccines and other applications |
| CA2589034C (en) | 2004-11-02 | 2016-05-31 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Compositions and methods for treating hyperproliferative disorders |
| GB0428394D0 (en) | 2004-12-24 | 2005-02-02 | Chiron Srl | Saccharide conjugate vaccines |
| US8110196B2 (en) | 2005-04-29 | 2012-02-07 | Polytopas LLC | Methods and compositions for polytopic vaccination |
| US20070104689A1 (en) * | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
| US20100111973A1 (en) | 2006-09-22 | 2010-05-06 | Glenn Dranoff | Methods for treating mica-related disorders |
| US8182809B1 (en) * | 2008-09-08 | 2012-05-22 | University Of Washington | Methods for treating cancer by inhibiting MIC shedding |
| US20120269721A1 (en) | 2009-10-12 | 2012-10-25 | The Regents Of The University Of California | Targeted nanoclusters and methods of their use |
| US8889044B2 (en) | 2009-12-18 | 2014-11-18 | Kao Corporation | Method for producing mesoporous silica particles |
| JP5603063B2 (en) | 2009-12-21 | 2014-10-08 | 花王株式会社 | Method for producing composite silica particles |
| RU2489169C2 (en) * | 2010-10-12 | 2013-08-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Новосибирский национальный исследовательский государственный университет" (Новосибирский государственный университет, НГУ) | Method of treating oncological diseases |
| EP2758072A1 (en) * | 2011-09-23 | 2014-07-30 | University Of Oslo | Vaccibodies targeted to cross-presenting dendritic cells |
| PL2760471T3 (en) | 2011-09-30 | 2017-07-31 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides |
| RU2656183C2 (en) * | 2012-02-07 | 2018-05-31 | Иннейт Фарма | Mica binding agents |
| DK2838515T3 (en) | 2012-04-16 | 2020-02-24 | Harvard College | MESOPOROUS SILICON Dioxide COMPOSITIONS FOR MODULATING IMMUNE RESPONSES |
| AU2014229476B2 (en) * | 2013-03-15 | 2019-07-11 | Novelogics Biotechnology, Inc. | Antibodies to MICA and MICB proteins |
| EP2970908B1 (en) | 2013-03-15 | 2019-12-25 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides |
| CA3124243A1 (en) * | 2014-03-14 | 2015-09-17 | Dana-Farber Cancer Institute, Inc. | Vaccine compositions and methods for restoring nkg2d pathway function against cancers |
-
2016
- 2016-12-05 CU CU2021000061A patent/CU20210061A7/en unknown
- 2016-12-05 BR BR112018010705A patent/BR112018010705A8/en active Search and Examination
- 2016-12-05 NZ NZ742663A patent/NZ742663A/en unknown
- 2016-12-05 SG SG11201804597TA patent/SG11201804597TA/en unknown
- 2016-12-05 PE PE2018001072A patent/PE20181158A1/en unknown
- 2016-12-05 AU AU2016362597A patent/AU2016362597C1/en active Active
- 2016-12-05 US US15/781,448 patent/US10993971B2/en active Active
- 2016-12-05 JP JP2018528691A patent/JP7099956B2/en active Active
- 2016-12-05 CR CR20230116A patent/CR20230116A/en unknown
- 2016-12-05 PE PE2022002801A patent/PE20230495A1/en unknown
- 2016-12-05 RU RU2018123307A patent/RU2747296C2/en active
- 2016-12-05 CA CA3005910A patent/CA3005910A1/en active Pending
- 2016-12-05 CU CU2018000050A patent/CU24609B1/en unknown
- 2016-12-05 KR KR1020187019140A patent/KR20180088458A/en not_active Ceased
- 2016-12-05 MY MYPI2018000849A patent/MY199248A/en unknown
- 2016-12-05 CR CR20180350A patent/CR20180350A/en unknown
- 2016-12-05 EA EA201891287A patent/EA201891287A1/en unknown
- 2016-12-05 RU RU2021109510A patent/RU2021109510A/en unknown
- 2016-12-05 EP EP16816550.4A patent/EP3383426A1/en active Pending
- 2016-12-05 TN TNP/2018/000187A patent/TN2018000187A1/en unknown
- 2016-12-05 WO PCT/US2016/064969 patent/WO2017096374A1/en active Application Filing
- 2016-12-05 MX MX2018006785A patent/MX2018006785A/en unknown
- 2016-12-05 CN CN201680080434.4A patent/CN108770343A/en active Pending
-
2018
- 2018-05-21 IL IL259490A patent/IL259490A/en unknown
- 2018-06-01 PH PH12018501170A patent/PH12018501170A1/en unknown
- 2018-06-01 CL CL2018001470A patent/CL2018001470A1/en unknown
- 2018-06-01 MX MX2022010194A patent/MX2022010194A/en unknown
- 2018-06-27 CO CONC2018/0006642A patent/CO2018006642A2/en unknown
-
2021
- 2021-02-19 US US17/180,183 patent/US20210299186A1/en not_active Abandoned
- 2021-05-13 CL CL2021001256A patent/CL2021001256A1/en unknown
-
2022
- 2022-03-21 AU AU2022201940A patent/AU2022201940B2/en active Active
- 2022-04-14 ZA ZA2022/04223A patent/ZA202204223B/en unknown
- 2022-06-30 JP JP2022105405A patent/JP7564842B2/en active Active
-
2023
- 2023-10-26 CL CL2023003217A patent/CL2023003217A1/en unknown
-
2024
- 2024-02-19 US US18/581,148 patent/US20250064863A1/en active Pending
- 2024-09-27 JP JP2024167997A patent/JP2024177207A/en active Pending
-
2025
- 2025-08-08 AU AU2025213685A patent/AU2025213685A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201804597TA (en) | Vaccination with mica/b alpha 3 domain for the treatment of cancer | |
| SG11201901548SA (en) | Anti-tim-3 antibodies and use thereof | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201908971RA (en) | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201907402SA (en) | Population-based immunogenic peptide identification platform | |
| SG11201809764XA (en) | Humanized anti-il-1r3 antibodies | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201805375PA (en) | Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
| SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201807720TA (en) | Methods and systems for determining antibiotic susceptibility | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201901347UA (en) | Compositions and methods for cancer immunotherapy |